Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash from Investing Activities (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Cash from Investing Activities data on record, last reported at -$962000.0 in Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 10588.89% year-over-year to -$962000.0; the TTM value through Sep 2025 reached -$3.5 million, down 540.51%, while the annual FY2024 figure was -$120000.0, 99.59% up from the prior year.
  • Cash from Investing Activities reached -$962000.0 in Q3 2025 per TNXP's latest filing, up from -$2.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$3000.0 in Q4 2024 and bottomed at -$24.0 million in Q2 2023.
  • Average Cash from Investing Activities over 3 years is -$3.3 million, with a median of -$626000.0 recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: surged 99.3% in 2024, then crashed 10588.89% in 2025.
  • A 3-year view of Cash from Investing Activities shows it stood at -$431000.0 in 2023, then soared by 99.3% to -$3000.0 in 2024, then plummeted by 31966.67% to -$962000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$962000.0 in Q3 2025, -$2.5 million in Q2 2025, and -$6000.0 in Q1 2025.